Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis

MLA

Twigg, S., et al. Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis. Feb. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....3376f449543dd43e115495f73db43214&authtype=sso&custid=ns315887.

APA

Twigg, S., Nikiphorou, E., Nam, J., Hunt, L., Mankia, K., Pentony, P., Freeston, J., Tan, A., & Emery, P. (2018). Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis.

Chicago

Twigg, S, E Nikiphorou, Jl Nam, L Hunt, K Mankia, Pe Pentony, Je Freeston, Al Tan, and P Emery. 2018. “Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis,” February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....3376f449543dd43e115495f73db43214&authtype=sso&custid=ns315887.